CaseXCase Series
Case studies: what the lab and LensAI™ deliver, measured.
Results from real programs: epitope mapping validated against X-ray crystallography, anti-drug-antibody risk prediction with clinical evidence, tumor-microenvironment engineering, and multi-cohort hybridoma campaigns against hard targets.
Spotlight:
LensAI Epitope Mapping matches X-ray crystallography
CaseXCase Series
Epitope Mapping
Case study collection:
Key study:
LensAI Epitope Mapping retains near X-ray precision on ‘unseen’ diverse clinically relevant complexes
CaseXCase Series
Epitope Mapping
Key study:
LensAI prediction of Anti-Drug Antibody incidence: evidence for clinical utility of ADA risk assessment
CaseXCase Series
Immunogenicity
Key study:
Antibody engineering for tumor microenvironment targeting
CaseXCase Series
Tumor Micro
Environment
From the lab and from LensAI™.
The same team behind these studies has run 3,000+ antibody programs with >98% B cell Select® discovery success*. 20+ publicly disclosed client antibodies have advanced from our lab into clinical development. Publicly disclosed programs only; additional client antibodies have advanced under partner confidentiality.
Let’s discover what’s next. With award-recognized science and solution-driven services, we work with teams to help advance diverse, high-quality candidates toward the clinic.
Talk to a scientist
A scientist replies within two business days.